|
1
|
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N–) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). Eur J Cancer 2017; 79:166-175. [DOI: 10.1016/j.ejca.2017.03.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 01/27/2017] [Accepted: 03/06/2017] [Indexed: 11/18/2022]
|
|
2
|
Amoroso V, Pedersini R, Sharratt P, Vassalli L, Ferrari L, Sigala S, Simoncini E, Berruti A. Should Adjuvant Weekly Paclitaxel Be Considered Less Efficacious Than Anthracyclines Plus Cyclophosphamide for Lower-Risk Patients With Early-Stage Breast Cancer? J Clin Oncol 2015; 33:290. [DOI: 10.1200/jco.2014.58.7923] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Vito Amoroso
- University of Brescia at Spedali Civili Hospital, Brescia, Italy
| | | | - Phoebe Sharratt
- Barts and The London School of Medicine and Dentistry, London, United Kingdom
| | | | - Laura Ferrari
- University of Brescia at Spedali Civili Hospital, Brescia, Italy
| | | | | | - Alfredo Berruti
- University of Brescia at Spedali Civili Hospital, Brescia, Italy
| |
Collapse
|